NECTIN4 and neoplasm: The researchers developed the ADC, enfortumab vedotin-ejfv/Padcev®, also known as ASG-22ME, comprising the anti-nectin-4 antibody linked to the microtubule-disrupting drug, monomethyl auristatin E. Treatment of human breast, bladder, pancreas and lung cancer xenografts in mouse models with enfortumab vedotin suppressed the growth of all four tumor types and ensured the regression of breast and bladder xenografts [59].